Fig. 7.

Anti-SEMA4D therapy reduces growth and vascularity of tumors resistant to anti-VEGF treatment. a CT26 cells were injected subcutaneously into nude mice along with a bolus of basement membrane extract. Control mice were treated with IgG isotype control (IgG) or anti-VEGF antibody (anti-VEGF) for 18 days. Treatment for some mice receiving anti-VEGF antibody was changed to IgG (anti-VEGF + IgG) or anti-SEMA4D antibody (anti-VEGF + anti-SEM A4D) starting at day 9, extending until the end of the experiment (day 18). Representative tumors are shown at the time of kill. b The results of tumor volume measurement in cm³ are shown (n = 10; *p <0.05; **p <0.01). c The results of tumor weights in mg in mice treated with IgG or anti-VEGF antibody for the duration of the experiment or in mice treated with anti-VEGF antibody from days 1 to 9 and then switched to IgG or anti-SEMA4D antibody injections for days 9–18 (n = 10; *p <0.05). d Immunofluorescence for CD31 as a measure of vascular density from tumors derived from CT26 cells. e Results of measurement of vascular content from these tumors determined by the average number of vessels in 10 high-power fields (hpf) for CD31-stained sections (*p <0.05)